Attention: You are using an outdated browser, device or you do not have the latest version of JavaScript downloaded and so this website may not work as expected. Please download the latest software or switch device to avoid further issues.
| 6 Nov 2024 | |
| WIB-Seattle News |
On October 29, Executive Women In Bio from the Seattle and San Francisco Bay Area chapters participated in a virtual event featuring a panel that discussed the path for women to become CEOs in the biotech industry. Moderated by Bizzy Balaraman of Russell Reynolds Associates, the discussion included insights from prominent leaders: Katie Fanning (CEO of Mozart Therapeutics), Julie Eastland (former CEO of Harpoon Therapeutics), Gail Maderis (former CEO of Antiva BioSciences), and Lynn Seeley (CEO of Lyell ImmunoPharma). These accomplished women shared personal experiences, motivations, and the pivotal moments that shaped their journeys to the top, offering valuable lessons for women seeking career advancement.
The panel opened with each speaker recounting the critical points in their careers, highlighting the risks they embraced to rise to CEO roles. They unanimously emphasized the importance of self-advocacy and clearly expressed aspirations to lead. The role of CEO, they noted, is all-encompassing, requiring strong hires and a robust peer network. Relationships with boards and investors were essential to each panelist, as they found board members to be vital advisors and allies. They also discussed the growth of Seattle’s life sciences community and the remarkable local talent pool. Key takeaways included the importance of self-advocacy, clearly communicating one’s strengths, taking strategic risks, and seizing opportunities. The panel showcased a group of resilient, confident women who support one another and continue to rise to every challenge.
Submitted by Jane Gross
